Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: A randomized controlled study and its pharmacokinetics analysis

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 3, 2015, Pages 651-655

  Li, Jie ^a   Chen, Rong ^a   Ji, Mei ^a   Zou, Su Lan ^a   Zhu, Li Na ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Advanced NSCLC; Chronotherapy; Cisplatin; Population pharmacokinetics

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG CHRONOTHERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 84939569263     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2804-x     Document Type: Article

References (31)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584-594
2. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52:155-163
3. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E (2010) Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529
4. Nation Comprehensive Cancer Network (2013) Non-small cell lung cancer (version 2.2014). Available: http://www.nccn.org/professionals/physician-gls/pdf/nscl.Pdf. Accessed 21 Jan 2014
5. Azzoli CG, Temin S, Giaccone G (2012) 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract/Am Soc Clin Oncol 8:63-66
6. Azzoli CG, Giaccone G, Temin S (2010) American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract/Am Soc Clin Oncol 6:39-43
7. Levi F (2006) Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control 17:611-621
8. Levi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, Isacobelli S, Adam R, Kunstlinger F, Gastiaburu J, Bismuth H, Jasmin C, Misset JL (1994) Chronomodulated versus fixed-infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86:1608-1617
9. Focan C, Denis B, Kreutz F, Focan-Henrard D, Levi F (1995) Ambulatory chronochemotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. J Infus Chemother 5:148-152
10. Satoh T, Omuro Y, Sasaki Y, Hamamoto Y, Boku N, Tamura T, Ohtsu A (2012) Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer. Cancer Chemother Pharmacol 69:949-955
11. Sebestyen J, Garg U, Lewing KB, Warady BA, Abdel-Rahman S, Blowey DL (2010) Cisplatin pharmacokinetics in a child receiving peritoneal dialysis. Pediatr Nephrol 25:1185-1189
12. Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, Eisenfeld A, Singer JW, Oldham FB (2009) A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol 63:903-910
13. Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB (2008) Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. Cancer Chemother Pharmacol 64:233-241
14. Urien S, Brain E, Bugat R, Pivot X, Lochon I, Van ML, Vauzelle F, Lokiec F (2005) Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 55:55-60
15. Ramon-Lopez A, Escudero-Ortiz V, Carbonell V, Perez-Ruixo JJ, Valenzuela B (2012) Population pharmacokinetics applied to optimising cisplatin doses in cancer patients. Farm Hosp 36:392-402
16. Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57:756-763
17. de Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A (2004) Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 54:105-112
18. Ishibashi T, Yano Y, Oguma T (2003) Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 56:205-213
19. Hanada K, Nishijima K, Ogata H, Atagi S, Kawahara M (2001) Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jpn J Clin Oncol 31:179-184
20. Kurihara N, Kubota T, Hoshiya Y, Otani Y, Ando N, Kumai K, Kitajima M (1996) Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J Surg Oncol 62:135-138
21. Zhang M (1992) Clinical pharmacokinetics of cis-diamminedichloroplatinum (DDP). Zhonghua Zhong Liu Za Zhi 14:67-69
22. Hrushesky WJ (1985) Circadian timing of cancer chemotherapy. Science 228:73-75
23. Levi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset JL, Regensberg C, Vannetzel JM, Reinberg A, Mathe G (1990) Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol 8:705-714
24. Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57:756-763
25. Chen Rong, Li Jie, Wen-wei Hu, Wang Ming-li, Zou Su-lan, Miao Li-yan (2013) Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program. Cancer Chemother Pharmacol 72:1111-1123
26. Pasquale F, Lévi Francis, Bjarnason Georg A (2010) Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev 62:979-1001
27. Loning Fu, Pelicano H, Liu Jinsong, Huang Peng, Lee Cheng Chi (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41-50
28. Gachon F, Olela F, Schaad O, Descombes P, Schibler U (2006) The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab 4:25-36
29. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler H (2006) The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 22:375-382
30. Goldbeter A, Claude D (2002) Time-patterned drug administration: insights from a modeling approach. Chronobiol Int 19:157-175
31. Altinoka A, Levi F, Goldbetera A (2009) Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci 36:20-38